The Portfolio · BriefAll articles →

LUPIN · Lupin Limited · NSE · Filed 23 Oct · 1 min read

Lupin Names Brian Savage as President, Chief Legal Officer

The former Teva executive will lead Lupin's global legal, compliance and intellectual property functions, based in New Jersey.

The appointment

Lupin Limited has appointed **Brian Savage** as President, Chief Legal Officer. Per the filing, Savage will lead the company's global Legal, Compliance, and Intellectual Property Management Group (IPMG) functions, and will be based in New Jersey. The disclosure was made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations.

Who he is

According to the filing, Savage joins from Teva Pharmaceuticals, where he held several senior leadership roles since 2015, most recently as Executive Vice President and Interim Global Chief Legal Officer. He also led Teva's global litigation strategy and served as General Counsel for its U.S. Generics business, and earlier practised law at Dechert LLP. He holds a J.D. from Yale Law School and a B.A. from the University of Pennsylvania.

Commenting on the appointment, CEO Vinita Gupta and Managing Director Nilesh Gupta framed the hire around strengthening Lupin's governance framework and navigating an evolving regulatory environment.

The Chief Legal Officer role spans legal, compliance and intellectual property for a company with large generics exposure in the U.S. market — areas where regulatory and litigation matters can bear on a pharma business. The filing records who now leads those functions, without disclosing terms or financial detail.

Share this

The brief

You just read one filing on Lupin. We do this every morning — for the stocks you own.

A calm, cited reading of your own holdings, delivered daily on Telegram or email. No tips.

Free during the pilot.

Read all articles